Medgenics, Inc.’s Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients

MISGAV, Israel--(BUSINESS WIRE)--Medgenics (AIM: MEDG) (AIM: MEDU) is pleased to announce that the latest, encouraging results of the Company’s ongoing EPODURE Biopump Phase I/II Clinical Trial will be presented at the 45th Conference of the Israeli Society of Nephrology and Hypertension, in Israel on March 27, 2009.